Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its second quarter 2017 financial results on Monday, August 7, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.
The dial-in numbers for the conference call are (844) 579-6824 for domestic callers and (763) 488-9145 for international callers, and the reservation number for both is 53628132. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them to send in questions to email@example.com. E-mail questions will be accepted until 4:00 p.m. Eastern / 1:00 p.m. Pacific on Monday, August 7, 2017.
The live webinar of the call may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website.
Invitae Corporation (NYSE: NVTA) is one of the fastest growing genetic information companies in the U.S. Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising approximately 1,500 genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas, as well as clinical analysis of a 20,000-gene medical exome. Additionally, the company has created a Genome Network to connect patients, clinicians, advocacy organizations, researchers, and therapeutic developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. For more information, visit our website at invitae.com.
Source: Invitae Corporation